News | December 24, 2024
Ikena Oncology and Inmagene Biopharmaceuticals announce agreement for merger
The transaction is expected to result in approximately $175 million to support further development of IMG-007
The transaction is expected to result in approximately $175 million to support further development of IMG-007
A 40 minute daily Yoga routine, incorporating select asanas and pranayama, along with standard lifestyle interventions, can reduce the risk of developing diabetes by approximately 40%
This acquisition positions Suven as a key player in one of the fastest growing segments of the Pharma CDMO landscape
The new facility significantly increases Siegfried’s R&D capacity to drive development excellence and further growth
Modernization and supply chain diversity drive new growth
Net profit for the quarter grew by 254.2 per cent and stood at Rs. 20.9 crore
For Q2, Akums reported a consolidated total income of Rs. 1,046.6 crore
Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies
Extension of long-term collaboration includes construction of new customer-dedicated bioconjugation capacity in Visp (CH) and commercial antibody supply of a new ADC
Financing includes new funding from leading global organizations Eli Lilly and Company and EDBI
Subscribe To Our Newsletter & Stay Updated
